Italy Sickle Cell Disease Drugs Market Report 2023 to 2030

Italy Sickle Cell Disease Drugs Market Analysis

$ 3999

Italy Sickle cell disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sickle cell disease Drugs is growing rapidly as a result of increasing prevalence of sickle cell disease , increasing investment for healthcare infrastructure, increase in the number of research and development activities, Support provided by governments of different countries, patient advocacy programmes and incentives provided by regulatory authorities. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.

ID: IN10ITRD112 CATEGORY: Rare Diseases GEOGRAPHY: Italy AUTHOR: Nipun Arora

Buy Now

Italy Sickle Cell Disease Drugs Market Analysis Summary

Italy Sickle Cell Disease Drugs Market is valued at around $57.12 Mn in 2022 and is projected to reach $142.45 Mn by 2030, exhibiting a CAGR of 12.1% during the forecast period 2023-2030.

Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of abnormal haemoglobin that causes red blood cells to become rigid and sickle-shaped. It happens due to a mutation on the sixth position of the beta chain of hemoglobin where glutamic acid amino acid gets converted into valine. Bone marrow transplantation is the only permanent cure for SCD, it is usually reserved for individuals under the age of 16 since bone marrow transplant risk in adults is too great. Symptomatic relief and palliative care are also done for this disease. Hydroxyurea and Endari are the only two licensed medicines available for this disease. Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Bluebird Bio, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Merck & Co., Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, AbbVie Inc are the key global market players operating in sickle cell disease Drugs market.

Market Dynamics

Market Drivers

Increasing prevalence of sickle cell disease.

Increasing investment in healthcare infrastructure

Increase in the number of research and development activities, Support provided by governments of different countries

Patient advocacy programmes and incentives provided by regulatory authorities like orphan drug designations. All these factors act as market growth drivers.

Market Restraints

High cost associated with treatment, lack of skilled professionals and physicians for treatment, lack of reimbursement policies and skilled professionals for treatment. All these act as restraints of sickle cell disease drug market development.

Notable deals in the Sickle cell disease Drugs market

In December 2021, Oxbryta (voxelotor) was approved by US FDA for treating sickle cell disease in patients aged 4 up to 11 years.

In May 2022, multiple daily doses of GBT601, Global Blood Therapeutics (GBT) experimental oral therapy for sickle cell disease (SCD), were well tolerated and showed promising pharmacological and efficacy signals in six patients in a phase I trial clinical trial.

Key players

Novartis Pfizer Sanofi Roche Vertex Pharmaceuticals GlaxoSmithKline Bluebird Bio CRISPR Therapeutics Sangamo Therapeutics Intercept Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Italy Sickle cell disease Drugs market

By Type

Sickle Cell Anemia
Sickle Hemoglobin- C Disease
Sickle Beta-Plus Thalassemia
Sickle Hemoglobin-D Disease
Sickle Hemoglobin-O Disease
Others

By Diagnosis

Screening Tests
New-born Screening
Prenatal Screening
Others

By Treatment

Disease Modifying Therapies
Gene therapies
Gene editing therapies
Targeted therapies
Symptomatic Treatments
Hydroxyurea
Blood Transfusion
Bone Marrow Transplantation
Penicillin
Analgesics

By Route of Administration

Oral
Parenteral
Others

By End-Users

Hospitals
Specialty Clinics
Homecare
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.